We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Issues Guidance on Consolidating ANDAs Amid Generic Backlog
CDER Issues Guidance on Consolidating ANDAs Amid Generic Backlog
In an effort to ease a major generics approval backlog, the FDA is advising generic drugmakers and regulators on how best to streamline ANDAs of varying strengths into a single application.